The speckling domain of the Wilms tumor suppressor WT1 overlaps with the transcriptional repression domain  by Herzer, Ute et al.
The speckling domain of the Wilms tumor suppressor WT1 overlaps with
the transcriptional repression domain
Ute Herzer, Bertram Lutz, Kristina Hartmann, Christoph Englert*
Institut fu«r Toxikologie und Genetik, Forschungszentrum Karlsruhe, Hermann von Helmholtz-Platz 1, 76021 Karlsruhe, Germany
Received 8 February 2001; accepted 8 March 2001
First published online 23 March 2001
Edited by Julio Celis
Abstract The Wilms tumor suppressor gene WT1 encodes a
zinc finger protein, expressed as different splicing variants, that
has all the hallmarks of a transcription factor. The 3KTS form
of WT1 displays a homogeneous localization within the nucleus
and has been shown to activate or repress the activity of various
target genes. In contrast, the WT1(+KTS) variant demonstrates
a speckled pattern of expression within the nucleus. This and its
association with factors of the splicing machinery has led to the
hypothesis that WT1(+KTS) might play a role in post-
transcriptional processes. By the generation of a series of
deletion constructs and subsequent immunofluorescence analysis,
we have identified and characterized the domain which is
responsible for the localization of WT1 variants in nuclear
speckles. The speckling domain comprises amino acids 76^120
within the N-terminus of WT1 and is sufficient to target other
proteins into distinct nuclear domains. Interestingly the WT1
speckling domain does not overlap with the domain required for
interaction with the splicing factor U2AF65 but overlaps with the
transcriptional repression domain. Thus our data challenge the
view that association of WT1 with spliceosomes is responsible for
the speckling phenotype. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The Wilms tumor suppressor gene WT1 encodes a four zinc
¢nger containing protein which is essential for the develop-
ment of various organs including the kidneys, gonads, heart
and spleen [1^3]. Mutations in WT1 predispose humans to the
generation of Wilms tumor, a pediatric kidney cancer [4,5], as
well as other, more complex diseases like the Denys^Drash [6]
and Frasier syndromes [7^9]. The latter are both characterized
by progressive nephropathy and genital malformations. Based
on these phenotypes and the expression pattern, it is generally
assumed that WT1 plays a pivotal role in mesenchymal^epi-
thelial transitions [10].
WT1, which is encoded by 10 exons, is expressed as a 36^62
kDa protein family that arises because of three alternative
sites of translation initiation [11,12]. There are four main
WT1 protein isoforms with molecular masses of 52^54 kDa
which are generated by two alternative splicing events of the
WT1 mRNA. Alternative splice I comprises exon 5, which
encodes 17 amino acids in the central part of the protein.
The functional consequences of the inclusion of exon 5 have
not yet been de¢ned clearly. Alternative splice II results from
use of an alternative splice donor sequence between exons 9
and 10. Its insertion leads to three additional amino acids (the
KTS sequence) that disrupt the spacing between zinc ¢ngers 3
and 4. These splice variants are expressed at a constant ratio
(+KTS:3KTSW2:1) [13].
There is biochemical and genetic evidence that points to
di¡erent functions for the 3KTS and +KTS variants of
WT1 [14]. Most notably, the alternatively spliced forms of
WT1 localize to di¡erent subnuclear compartments. While
WT1(3KTS) is di¡usely localized throughout the nucleus,
WT1(+KTS) is expressed in a speckled pattern within the
nucleus [15,16]. These observations suggest that di¡erent
splice forms of WT1 exert their role at di¡erent sites in the
nucleus.
Although WT1 has many properties that are typical of a
transcription factor including a glutamine/proline-rich N-ter-
minus, activation and repression domains [17^19], nuclear lo-
calization signals [20] and four Cys2^His2 zinc ¢ngers at the
C-terminus, it is primarily the 3KTS form of WT1 which has
been shown to be transcriptionally active [14]. The +KTS
form on the other hand has been demonstrated to be associ-
ated with splice factors and could be colocalized and coimmu-
noprecipitated with antisera against proteins found in spliceo-
somes or coiled bodies [15]. Localization of speckling WT1
variants, however, was clearly distinct from that of the essen-
tial splicing factor SC35 [16]. Despite this controversy it re-
mains a possibility that +KTS variants of WT1 are involved
in post-transcriptional processes, a hypothesis which is under-
scored by the recent ¢nding that WT1, particularly the +KTS
variant, speci¢cally and directly associates with the splicing
factor U2AF65 [21]. By gel ¢ltration and sedimentation anal-
ysis, WT1 has also been shown to be present in ribonucleo-
protein complexes [22].
There are several reports about the ability of WT1 to bind
RNA. Computer modeling has demonstrated that WT1 pos-
sesses in its N-terminus a potential RNA recognition motif
similar to that in constitutive splicing factors [23]. Also, the
zinc ¢nger domain of WT1 has been shown to bind to RNA
derived from exon 2 of the insulin-like growth factor II gene
(Igf-2). In this case the WT1(+KTS) form bound the RNA
probe with greater a⁄nity than WT1(3KTS) [24]. In a more
systematic search, the SELEX (systematic evolution of ligands
by exponential enrichment) method has been employed to
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identify WT1 binding sequences from a random RNA pool.
Three di¡erent groups of RNA ligands which were speci¢cally
bound by WT1 were selected. In contrast to earlier work,
however, in this case the WT1(+KTS) isoform was unable
to bind the identi¢ed RNAs [25]. Given the partly contradict-
ing results, the signi¢cance of these ¢ndings has to remain
elusive until a functional role for WT1 in RNA processing
has been de¢ned.
In order to eventually clarify the biochemical properties of
the WT1 variants we have identi¢ed and characterized the
domain which is responsible for the speckling phenotype of
WT1. This domain which comprises amino acids 76^120 over-
laps with the transcriptional repression domain of WT1 and is
su⁄cient to confer ‘speckling’ to other proteins.
2. Materials and methods
2.1. Generation of expression constructs
All constructs used in this study are based on the murine WT1
sequence which is more than 95% identical at the amino acid level
to its human counterpart [26]. WT1 deletion constructs were gener-
ated by polymerase chain reaction (PCR)-mediated ampli¢cation of
the indicated fragments and subsequent cloning into the EcoRI and
ApaI sites of the eukaryotic expression vector Rc/CMV (Invitrogen).
The vector had previously been modi¢ed so that the second EcoRI
site (position 1744) was deleted. In addition, two complementary oli-
gonucleotides had been inserted between the HindIII and EcoRI sites
constituting an HA-epitope tag. A sequence encoding a nuclear local-
ization signal (KKKRKVD) was inserted into the 3P-end of each
deletion construct. Construct CHD was made by amplifying the
full-length WT1 cDNA (harboring both alternative splice sequences)
by PCR using primers with EcoRI and ApaI sites at the 5P- and 3P-
termini, respectively. The resulting fragment was then cloned into the
EcoRI and ApaI sites of Rc/CMV which also carried an HA-tag.
CHDv was generated by digestion of CHD with BssSI and subse-
quent religation. By this procedure amino acids 84^177 of WT1 are
deleted.
For the generation of the glutathione S-transferase (GST) fusion
construct, a fragment of WT1 encompassing codons 76^160 was am-
pli¢ed by PCR and ligated into the BamHI and KpnI sites of the
vector pEBG (described in [27]). A sequence encoding a nuclear local-
ization signal (KKKRKVD) was inserted into the 3P-end of the ex-
pression construct. As a control a construct was used in which a pair
of oligonucleotides encoding a nuclear localization signal were ligated
into the BamHI and KpnI sites of pEBG.
2.2. Cell culture and transfections
The human osteosarcoma cell line U2OS was obtained from the
American Type Culture Collection (ATCC), COS-7 cells from the
European Collection of Cell Cultures (ECACC). Cell lines were cul-
tured in Dulbecco’s modi¢ed Eagle’s medium supplemented with 10%
fetal calf serum. Transient transfections were done using the Super-
Fect reagent (Qiagen) according to the manufacturer’s recommenda-
tions. For the colocalization analysis the SD3 cell line has been used
[28] which harbors an inducible wild-type WT1 allele containing both
alternative splice sequences.
2.3. Antibodies and immuno£uorescence analysis
For immuno£uorescence analysis, cells were grown on coverslips,
¢xed with 4% (w/v) paraformaldehyde, permeabilized with 1% Non-
idet P-40 in 10 mM glycine, preadsorbed with 3% (w/v) bovine serum
albumin and exposed to antibodies C-19 (rabbit polyclonal anti-WT1,
Santa Cruz), 12CA5 (mouse monoclonal anti-HA, Roche) or to a
monoclonal anti-GST antibody (Sigma Immunochemicals). Coverslips
were then exposed to rhodamine-conjugated goat anti-rabbit or £uo-
rescein-conjugated goat anti-mouse antibody. Samples were examined
by using a Zeiss Axiovert 135 microscope. For colocalization analysis
the Openlab digital imaging system (Improvision, UK) was used.
2.4. Western blotting analysis
For Western blotting, cellular lysates were extracted with RIPA
bu¡er (10 mM Tris^HCl, pH 7.4/150 mM NaCl/1% Triton X-100/
1% sodium deoxycholate/0.1% sodium dodecyl sulfate (SDS)), electro-
phoretically separated on a 12% SDS^PAGE and transferred onto a
PVDF membrane (Immobilon-P; Millipore). Blots were probed with
the anti-HA antibody 12CA5, followed by horseradish peroxidase-
coupled goat anti-mouse antibody and enhanced chemiluminescence
analysis (ECL; Amersham).
Fig. 1. Identi¢cation of the WT1 speckling domain. A: Western
blot analysis using protein extracts from U2OS cells transfected
with the constructs indicated. An anti-HA antibody was used for
protein detection. Positions of marker proteins (in kDa) are indi-
cated. B: Subnuclear localization of WT1 proteins determined by
staining with anti-HA antibody followed by indirect immuno£uores-
cence analysis. U2OS cells were transfected with the constructs indi-
cated. Except where construct WT1/1^91 has been used, only the
nuclei are stained. Bar, 5 Wm.
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3. Results
3.1. The minimal speckling domain of WT1 comprises amino
acids 76^120
Previous work has demonstrated that the domain respon-
sible for the localization of WT1 in speckles must be con-
tained in the N-terminus of the molecule. This is based on
the observation that a WT1 mutant form with a deletion of
the C-terminal zinc ¢nger domain can also be found in these
subnuclear compartments [16]. We have therefore generated a
series of N- and C-terminal deletions of the WT1 amino-ter-
minal domain. All constructs harbored an HA-tag as well as a
nuclear localization signal and were driven from a CMV pro-
moter. Following Western blot analysis to ensure correct ex-
pression of all constructs (Fig. 1A), the localization of the
respective gene products was analyzed by immuno£uores-
cence. As can be seen in Fig. 1B, proteins comprising the ¢rst
273, 182 or 120 amino acids of WT1 are localized in nuclear
speckles. Although clearly most of the cells expressing the
latter construct showed a speckled expression, the localization
to those nuclear domains was more stringent when construct
WT1/1^182 was used. Further deletion (WT1/1^91) results in
an ubiquitous distribution in both the nucleus and the cyto-
plasm. Most likely the polypeptide is too small to be e⁄-
ciently kept in the nucleus. These results demonstrate a re-
quirement for amino acid residues between positions 91 and
120 for WT1 to be targeted to nuclear speckles. In the case of
the N-terminally deleted WT1 mutants, WT1/76^273 demon-
strated a prominent speckling pattern whereas the WT1/99^
273 mutant showed a homogeneous nuclear expression pat-
tern. From these analyses we conclude that a minimal domain
containing amino acids 76^120 of WT1 is required for the
localization in nuclear speckles. Interestingly this domain al-
most perfectly overlaps with the WT1 domain responsible for
transcriptional repression which has been mapped between
amino acids 85 and 124 [17,19].
We next wanted to address the function of the speckling
domain in the context of the full-length WT1 molecule. Start-
Fig. 2. Localization of wild-type and speckling domain-de¢cient mu-
tant WT1 protein. Immuno£uorescence analysis of the WT1(+KTS)
isoform (A) and a mutant variant lacking amino acids 84^177 (B).
Human U2OS cells were used for this experiment. Protein detection
was carried out using an anti-WT1 antibody. Bar, 2 Wm.
C
Fig. 3. Colocalization of wild-type WT1(+KTS) and a WT1 mutant
form using digital deconvolution microscopy. A Saos-2 cell line
which stably expresses a WT1(+KTS) isoform (SD3, see [28]) was
transfected with the WT1/1^273 construct. Detection of the wild-
type WT1 protein was carried out with the anti-WT1 antibody C-19
(A), the mutant WT1 protein was visualized using the anti-HA anti-
body 12CA5 (B). In C the upper two frames have been merged.
The yellow color indicates colocalization of the wild-type and mu-
tant proteins. Note that only the upper cell has been successfully
transfected with the mutant construct, the bottom cell expresses
only wild-type protein. Bar, 2 Wm.
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ing from a wild-type WT1(+KTS) cDNA (named CHD) we
have deleted amino acids 84^177 harboring those amino acids
required for speckling. This construct was named CHDv and
was expressed as e⁄ciently as the wild-type version (Fig. 1A).
The human osteosarcoma cell line U2OS was transfected with
both constructs and localization of the gene products was
analyzed by immuno£uorescence (Fig. 2). The CHD protein
could be found throughout the nucleus but also in de¢ned
nuclear speckles whereas CHDv harboring the internal dele-
tion was uniformly distributed within the nucleus. This obser-
vation was independent of the cell line used and has been
con¢rmed in COS-7 cells as well as in the murine mesonephric
M15 cell line (data not shown). Thus deletion of an internal
WT1 fragment encompassing amino acids 84^177 renders the
protein unable to localize to nuclear speckles con¢rming the
previous deletion analysis.
3.2. Wild-type and mutant WT1 localize to identical subnuclear
structures
As can be seen in Fig. 1, the shape, size and number of
WT1-associated speckles are not always identical. We there-
fore wanted to investigate whether the appearance of the
speckles is dependent on the structure and length of the
WT1 protein and whether wild-type and mutant WT1 forms
localize to the same nuclear foci. For this analysis we have
transfected a cell line harboring an inducible full-length
WT1(+KTS) transgene with a construct encoding WT1/1^
273. Nuclear localization of the di¡erent WT1 forms was ex-
amined by immuno£uorescence analysis using digital decon-
volution microscopy (Fig. 3). For the wild-type form an anti-
body was used which is directed against the C-terminal amino
acids of WT1, a region missing in the mutant form (Fig. 3A).
The mutant protein was detected with an HA antibody which
does not recognize the wild-type protein (Fig. 3B). Cells which
expressed both the mutant as well as the wild-type WT1 form
demonstrated colocalization of both proteins in subnuclear
structures (Fig. 3C). This observation con¢rms the conclu-
sions drawn from the experiments described above in that
the localization of WT1 in nuclear speckles does not depend
on the presence of the zinc ¢nger region which is responsible
for nucleic acid binding. Also, the structure of the WT1 pro-
tein does not seem to in£uence the shape, size and number
of speckles it localizes to. We conclude from this experiment
that the WT1-associated speckles do not re£ect properties of
the respective WT1 protein but are de¢ned nuclear compart-
ments.
3.3. The speckling domain of WT1 is su⁄cient for the
localization in subnuclear structures
After having de¢ned the amino acids which are necessary
for the localization of WT1 in speckles we wanted to inves-
tigate whether this particular domain of WT1 was also su⁄-
cient for the localization. To address this question we have
fused WT1 amino acids 76^160 together with a nuclear local-
ization signal to GST. Here we have used a slightly extended
form of the minimal speckling domain de¢ned above because
WT1/1^160 was localized in speckles in nearly 100% of all
nuclei examined, whereas the minimal domain (amino acids
76^120) was less stringent in that regard. As GST is normally
localized in both the cytoplasm as well as the nucleus (data
not shown) we have used a GST carrying the same nuclear
localization signal as the GST^WT1 fusion protein as a con-
trol for this experiment. Immuno£uorescence analysis of cells
transfected with a GST^NLS encoding construct revealed a
uniform nuclear staining pattern (Fig. 4A,B). In contrast, the
fusion protein of WT1 and GST could be found in clearly
demarcated nuclear speckles (Fig. 4B,D). Number and ap-
pearance of these structures were very similar to the ones
associated with the WT1 forms that can be seen in Fig. 1
and independent of the cell type used. The localization of a
fusion protein consisting of GST and the N-terminal fragment
of WT1 indicates that the WT1 speckling domain is not only
necessary but also su⁄cient for the localization in nuclear
speckles. In addition, this domain can be transferred onto
other proteins which are then also targeted to this nuclear
compartment.
4. Discussion
Using a series of WT1 deletions we have identi¢ed the do-
main which is responsible for the speckling phenotype of
WT1. This domain is located within the N-terminus of the
protein and comprises amino acids 76^120. It has been shown
earlier that a small fraction of WT1 in a cell, preferentially the
+KTS variants, are physically associated with the splicing
factor U2AF65 [21]. Since factors involved in splicing often
localize in nuclear speckles, this would suggest that the speck-
ling phenotype of WT1 is caused by its association with
U2AF65. In the same report, however, it is stated that the
binding to U2AF65 is not a prerequisite for the speckled dis-
tribution of WT1. This is con¢rmed by the observation that
binding of U2AF65 required the C-terminal domain of WT1
(amino acids 181^449, [21]), whereas our data clearly demon-
strate localization of the speckling domain within the N-ter-
minal part of the molecule. Thus, the localization in speckles
and the association with factors of the splicing machinery, at
Fig. 4. The WT1 speckling domain is su⁄cient to target GST into
nuclear speckles. U2OS (A,B) and COS cells (C,D) were transfected
with a construct encoding either GST alone (A,C) or a fusion be-
tween GST and amino acids 76^160 of WT1 (B,D). Both gene prod-
ucts carry a C-terminal nuclear localization signal sequence. The
proteins were visualized using an anti-GST antibody. Only the nu-
clei of transfected cells are shown. Bar, 2 Wm.
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least with regard to U2AF65, are separable features of WT1.
This observation challenges the view that WT1’s association
with the mRNA splicing machinery is responsible for the
speckling phenotype.
WT1 has been shown to possess distinct transcriptional
activation and repression domains. A detailed analysis re-
vealed that residues 85^124 are responsible for the transcrip-
tional repression function of WT1 whereas amino acids 181^
250 are required to activate transcription [17^19]. It is inter-
esting to note that the domain which we have identi¢ed as the
speckling domain of WT1 shows signi¢cant overlap with the
repression domain of this molecule. Given that only a fraction
of WT1 seems to be associated with splicing factors [21] or in
other instances colocalization with these factors cannot be
observed [16] one could speculate that there are other factors
which WT1 might be associated with in nuclear speckles.
These could be factors mediating transcriptional repression.
Although there is accumulating evidence that WT1 can func-
tion as a transcriptional activator [29^31], WT1 had initially
been characterized as a transcriptional repressor and there are
a number of reports in which the 3KTS and the +KTS var-
iants repress transcription equally well [32]. How transcrip-
tional repression and the localization in speckles relate to
each other (whether for example speckles serve as storage sites
for repressor molecules) is at present unclear and must await
further functional characterization of these subnuclear struc-
tures. Interestingly, some members of the family of human
histone deacetylases, which serve as components of transcrip-
tional repressor complexes, have also been found to be local-
ized in discrete nuclear foci [33].
Our results demonstrate that the speckling domain of the
WT1 protein is located within the N-terminus of the molecule.
The original observation with regard to the di¡erential local-
ization, however, was made with the +KTS and 3KTS var-
iants of WT1. The di¡erence between those splice forms is
limited to the C-terminus of the molecule. How can one en-
visage that a structural motif within the zinc ¢nger region of
WT1 can a¡ect the di¡erential localization of the molecule for
which an N-terminal domain is required? One possibility is
that the localization of WT1 is guided by di¡erential a⁄nities.
The 3KTS form of WT1 might for example have a much
higher a⁄nity for DNA than the +KTS form and therefore
override an association mediated by the speckling domain.
Conversely, the +KTS form might preferentially be associated
with speckles since its DNA binding a⁄nity is not su⁄ciently
high. It has recently been reported that the introduction of a
point mutation into the zinc ¢nger region of a 3KTS variant
of WT1 leading to the loss of DNA binding results in en-
hanced colocalization with splice factors, i.e. speckling [21].
This observation supports the ‘competition’ hypothesis. Alter-
natively there might be an intramolecular interaction between
the N- and the C-terminus of WT1 which might in£uence its
biochemical properties.
The identi¢cation of the speckling domain of WT1 should
prove useful since it can serve as a tool to identify components
with which WT1 is associated. This in turn will help to clarify
whether the di¡erent splice forms of WT1 exert their function
at the transcriptional and/or post-transcriptional level.
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